According to the latest disclosed terms of the revolving credit agreement, medical device giant Boston Scientific Corporation has obtained a significant financing authorization.

The company is permitted, under the framework of the agreement, to apply for a 364-day delayed draw term loan with a maximum limit of $5 billion. This financing arrangement adopts a delayed draw mechanism, which means that Boston Scientific can flexibly withdraw loan funds in batches according to actual funding needs within the validity period of the agreement. Such loan structures typically provide enterprises with more efficient cash flow management solutions while optimizing the cost of capital utilization. The 364-day loan term is designed to ensure coverage of the company's medium-term operational funding needs and also reflects the financial institution's recognition of Boston Scientific's creditworthiness and debt repayment ability. This financing tool will provide strong capital support for the company's future business expansion, R&D investment, or strategic acquisitions.